^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    4d
    PiNACLE-H2H: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (clinicaltrials.gov)
    P3, N=400, Recruiting, Lyell Immunopharma, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • rondecabtagene autoleucel (LYL314)
    8d
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, Janssen Research & Development, LLC | Trial completion date: Feb 2039 --> Jan 2040
    Trial completion date
    |
    JNJ-9530
    9d
    A Phase 1 Open-label, Multiregional, Multicenter, BasketnStudy Evaluating the Safety and Efficacy of KITE-363, annAutologous Anti-CD19/CD20 CAR T-cell Therapy innParticipants with Relapsed/Refractory AutoimmunenNeurologic Diseases (ACTRN12625001346460)
    P1, N=52, Not yet recruiting, Kite, A Gilead Company
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • KITE-363
    12d
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=11, Terminated, The First Affiliated Hospital with Nanjing Medical University | N=33 --> 11 | Trial completion date: Jun 2028 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jun 2025; Achieve the proof of concept.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    17d
    Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    19d
    Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE (clinicaltrials.gov)
    P1, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    22d
    MB-CART2019.1 in Refractory Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=26, Not yet recruiting, Miltenyi Biomedicine GmbH | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    26d
    A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 ) (clinicaltrials.gov)
    P1, N=27, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    CRC-403: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov)
    P1, N=15, Terminated, Regeneron Pharmaceuticals | Phase classification: P1/2 --> P1 | Active, not recruiting --> Terminated; Sponsor Decision
    Phase classification • Trial termination
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    bbT369
    2ms
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=114, Recruiting, Kite, A Gilead Company | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2027 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    2ms
    CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma. (PubMed, Haematologica)
    Not available.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    2ms
    MPCT-012L: Study of LYL314 in Aggressive Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=270, Recruiting, Lyell Immunopharma, Inc. | Trial completion date: Jan 2028 --> Jun 2031 | Trial primary completion date: Aug 2026 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • fludarabine IV • rondecabtagene autoleucel (LYL314)